We are pleased to announce the launch of a new program that donates vital medicines to underserved communities in El Salvador. Working in collaboration with Americares and FUSAL, this effort ensures that everyone, regardless of their circumstances, has access to a #HealthyFuture. In El Salvador, many patients face significant barriers that prevent them from getting the treatments they need. Through this program, we are addressing critical health needs related to cardiovascular diseases, diabetes, respiratory illnesses and pain and palliative care. Our goal is to bring hope and healing to those who need it most. This program joins seven others providing treatments to underserved populations worldwide, and we are proud to have reached our goal of launching eight access to medicines programs by 2025 ahead of schedule. Programs like this are a testament to our commitment to #HealthEquity. By working closely with our partners, we deliver customized, localized solutions that truly make a difference. We invite you to read more about how we are bringing essential treatments to patients who otherwise wouldn’t have them: https://ow.ly/RvWN50SR0gp #HealthyPeople #Tevapharm #CommunityCare #PatientCentricity
About us
Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com. Please note that adverse effects for any of our products should be reported to: Safety.AE@teva.co.il Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
- Website
-
http://www.tevapharm.com
External link for Teva Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Tel-Aviv
- Type
- Public Company
- Specialties
- generic medicines, specialty medicines, CNS, active pharmaceutical ingredients, respiratory, biosimilars, biologics, pain care, migraine, and oncology
Locations
Employees at Teva Pharmaceuticals
Updates
-
When it comes to evolving research in movement disorders like #tardivedyskinesia (TD), a key part of our work involves presenting our findings at scientific conferences. We recently had the opportunity to ask our employees who are responsible for sharing Teva’s latest data and educating the scientific community more about TD why their work is so important. #TevaPharm #WeAreAllInForBetterHealth
-
Yesterday Teva CEO Richard Francis talked with CNBC “Money Movers” about our strong momentum, Q2 business performance, the progress on our #PivotToGrowth strategy and plans ahead. Watch the full interview on CNBC here: https://lnkd.in/e_YH4A8y. #QuarterlyResults #Q2Results #Earnings #Tevapharm View highlights from the interview below:
-
#ICYMI: Yesterday we shared Teva's business results for Q2 2024. Hear more about Teva’s performance in Q2 2024, how we're all in for better health, and the next steps we're taking on our #PivotToGrowth journey. Access a replay of the Q2 2024 investor webcast here: https://ow.ly/FovT50SOcGF Forward-looking statements are subject to the cautionary note included in our Q2 2024 press release. #QuarterlyResults #Earnings #Tevapharm #PivotToGrowth
-
📢 Tune in live 📢 Our Q2 2024 earnings call is starting in 30 minutes! Join CEO Richard Francis and the Teva leadership team live, and hear more about our business performance, the progress on our #PivotToGrowth strategy, and plans ahead. Join here: https://ow.ly/YZw950SO0bl #QuarterlyResults #Earnings #Tevapharm
-
“In the second quarter of 2024, we are encouraged by the positive momentum across each of the four pillars of our Pivot to Growth strategy. Teva's global revenues of $4.2 billion increased by 7% in U.S. dollars, or 11% in local currency terms compared to the second quarter of 2023, delivering strong growth driven by our generics and innovative business" - Richard Francis, Teva President and CEO We are pleased to share Teva’s Q2 2024 business results. View the full press release: https://lnkd.in/duejCq4X Forward-looking statements are subject to the cautionary note included in our Q2 2024 press release. #QuarterlyResults #Earnings #Tevapharm #PivotToGrowth
-
What is Teva’s Pivot to Growth strategy? Discover the four key pillars behind Teva’s growth, from new innovations in treatments for diseases that are on the rise worldwide to supporting patients with conditions including schizophrenia and migraine. Our strategy speaks to our Teva nature – being all in for better health, we work together to achieve remarkable things. Our direction is clear, and we are committed to keep raising the bar, in service of our patients, customers and healthcare systems. Discover more: https://ow.ly/21ng50SNecX #PivotToGrowth #WeAreAllInForBetterHealth #Innovation #Tevapharm
-
How can we empower patients, treating them as partners in their own health journey? Check out this thoughtful post from Alyssa Fenoglio, Global Head of Digital Commercial and a Teva Nexter, and join the conversation around patient empowerment. #Tevapharm #PatientEmpowerment #PatientsAreConsumers #TevaNexters
Global Marketing & Digital Executive | Purpose-Driven Leader | Transformation & Capability Expert | Keynote Speaker | P&G Alumni
🤝 Pharma friends, It's time we talked about empowering patients. ❤️ 👉 Let's face it, we've been stuck in our ways, treating patients like passengers in their own healthcare journey for far too long. 🚕 🌟 What if we took a page from our FMCG colleagues and considered our patients not just as prescription recipients, but as empowered health partners? Let's reimagine our approach: ✔️ Prescriptions as Collaborations: Let's move from patients as passive recipients to collaborative decision-makers. ✔️ Reimagine the Pharmacy Counter: Transform from a transaction counter to a health optimization hub for informed choices. ✔️ From Mystery Cabinet to Empowerment Toolkit: Translate the intimidating medicine cabinet into a personalized wellness toolkit. ✔️ Infuse AI, Digital, & Automation: To fuel the "new patient empowerment norm" in a personalized, democratized approach. 🔆 I know, I know - regulatory constraints are real. But they're not excuses for failing to innovate. We have a huge opportunity & responsibility to educate, engage, and empower patients (aka consumers) in their healthcare journeys. 🔔 So, pharma friends, are we up for this challenge? Can we shift our mindset and start treating patients like the savvy health consumers they could be? 💥 Let's shake things up. Who's with me? #PatientsareConsumers #PatientEmpowerment #PharmaChangemakers #PharmaCX #TevaNexter
-
Ready, set... Go! 🤸🏼🥇 🤼 The #Paris2024 Olympics kick off today, and it's the perfect time to introduce some of our very own talented athletes (and dedicated employees). Meet Mario Castro from Teva Mexico’s digital team, who is on his fifth major marathon (and counting!), and Juan José Pérez-Perruca Moreno from Teva EU's customer service, who recently completed a grueling 23km open-water swim for ALS, and now has his sights set on an Ironman. Both Mario and Juanjo acknowledge the power of sports on their wellbeing, personal development, and the people they’ve become. How do they overcome setbacks and what keeps them going? Read their stories here > https://ow.ly/QvaL50SK4Fk So, who are you rooting for in Paris 2024? Let us know in the comments below. 👇 #Paris2024 #ParisOlympics #OlympicGames #TevaAthletes #WellbeingAtTeva #Tevapharm
-
Strategic alliances in pharmaceutical development create opportunities to innovate new treatment options for patients. Collaborations enable partners to expand reach and leverage the collective strength of diverse resources. We’re proud to announce that, in partnership with Sanofi, we’ve accelerated our Phase 2b trial investigating anti-TL1A for moderate-to-severe inflammatory bowel disease (#IBD). Patients with #UlcerativeColitis and #CrohnsDisease have suffered too long without substantial progress, and we’re working to bring them the relief they need. Discover more: https://ow.ly/ZKtG50SJNBv #PivotToGrowth #TevaPharm #Innovation
Affiliated pages
Similar pages
Stock
TEVA
NYSE
20 minutes delay
$16.68
-0.31 (-1.825%)
- Open
- 16.03
- Low
- 15.81
- High
- 17.035
Data from Refinitiv
See more info on